Brought to you by 
Biovail, Kos sign series of CV and metabolic deals
16 May 2006
Executive Summary
For $104mm, specialty pharma company Kos Pharmaceuticals has licensed US rights to three cardiovascular products and three candidates in the cardiovascular and metabolic areas from drug delivery company Biovail (focuses on CV and CNS disorders). The series of deals is part of Biovail's restructuring of its US primary care marketing operations.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biovail, Kos sign series of CV and metabolic deals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice